Partha Kar argues that implementing NICE’s recommendation to delay the onset of type 1 diabetes with teplizumab within the NHS requires dedicated funding. The deadline for commissioners to make the treatment available within 90 days has passed, but a national implementation pathway, central leadership, funding, a public education programme, and ongoing mechanisms for identifying eligible patients remain underdeveloped. The article criticises the lack of necessary supporting resources for translating NICE drug recommendations into practical implementation across the NHS.
Source:BMJ · Read original